TheBodyPro news story
Researchers and clinicians are turning to new tools amidst an evolution in strategies for reducing cardiovascular risk in people with HIV. Findings from multiple studies presented at AIDS 2026 highlighted the potential of novel biomarkers and calculators that may refine risk stratification and define more precise targets for anti-inflammatory and immunomodulatory therapies.
“Cardiovascular disease is a tricky disease to study,” said Madeleine Durand, M.D., assistant clinical professor at the University of Montreal in Quebec. “Its landmark is a progressive, vastly asymptomatic accumulation of plaque with relatively rare clinical events — even though this is the disease that kills most humans on this planet.”
She noted that there were seven major adverse cardiovascular events per 1,000 person-years in the placebo arm of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). “So, we are in dire need of good, validated surrogate endpoints that will allow us to efficiently test new treatment strategies to diminish [the impact of] cardiovascular disease for people living with HIV,” she said.
Standard tools may underpredict cardiovascular risk for individuals with HIV. Combining standard risk calculators, blood protein tests, and imaging biomarkers may help eliminate some of the blind spots and improve care for people with HIV beyond viral suppression.
Read the full news story here.
Source : TheBodyPro
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.